【4506】住友ファーマ
製薬。精神神経、抗がん剤。親会社は住友化学。
売上高
営業利益
経常利益
当期利益
業績予想修正
対前回修正率
当初予想比較
決算期 | 日付 | 予・実 | 売上高 (百万円) | 対前回 | 営業利益 (百万円) | 対前回 | 経常利益 (百万円) | 対前回 | 当期利益 (百万円) | 対前回 |
---|---|---|---|---|---|---|---|---|---|---|
2025.03 | 2025/01/31 | 修正予 | 381,000 | ↑ | 21,000 | ↑ | - | - | 16,000 | ↑ |
2025.03 | 2024/10/30 | Q2予 | 338,000 | → | 0 | → | - | - | -16,000 | → |
2025.03 | 2024/07/31 | Q1予 | 338,000 | → | 0 | → | - | - | -16,000 | → |
2025.03 | 2024/05/14 | 当初予 | 338,000 | - | 0 | - | - | - | -16,000 | - |
2024.03 | 2024/05/14 | 実 | 314,558 | ↓ | -354,859 | ↑ | - | - | -314,969 | ↑ |
2024.03 | 2024/04/29 | 修正予 | 314,600 | ↓ | -354,900 | ↓ | - | - | -315,000 | ↓ |
2024.03 | 2024/01/31 | Q3予 | 317,000 | ↓ | -156,000 | ↓ | - | - | -141,000 | ↓ |
2024.03 | 2023/10/31 | Q2予 | 362,000 | → | -78,000 | → | - | - | -80,000 | → |
2024.03 | 2023/07/31 | Q1予 | 362,000 | → | -78,000 | → | - | - | -80,000 | → |
2024.03 | 2023/05/15 | 当初予 | 362,000 | - | -78,000 | - | - | - | -80,000 | - |
2023.03 | 2023/05/15 | 実 | 555,544 | ↑ | -76,979 | ↑ | - | - | -74,512 | ↓ |
2023.03 | 2023/04/28 | 修正予 | 555,500 | ↓ | -77,000 | ↓ | - | - | -74,500 | ↓ |
2023.03 | 2023/01/31 | Q3予 | 563,000 | ↓ | -27,000 | ↑ | - | - | -35,000 | ↓ |
2023.03 | 2022/10/31 | 修正予 | 604,000 | ↑ | -30,000 | ↓ | - | - | -15,000 | ↓ |
2023.03 | 2022/07/29 | Q1予 | 550,000 | → | 24,000 | → | - | - | 22,000 | → |
2023.03 | 2022/05/13 | 当初予 | 550,000 | - | 24,000 | - | - | - | 22,000 | - |
2022.03 | 2022/05/13 | 実 | 560,035 | ↑ | 60,234 | ↑ | - | - | 56,413 | ↑ |
2022.03 | 2022/04/28 | 修正予 | 560,000 | ↑ | 60,200 | ↑ | - | - | 56,400 | ↑ |
2022.03 | 2022/01/31 | Q3予 | 554,000 | ↓ | 55,000 | ↓ | - | - | 37,000 | ↓ |
2022.03 | 2021/10/27 | Q2予 | 578,000 | → | 61,000 | → | - | - | 41,000 | → |
2022.03 | 2021/07/29 | Q1予 | 578,000 | → | 61,000 | → | - | - | 41,000 | → |
2022.03 | 2021/05/12 | 当初予 | 578,000 | - | 61,000 | - | - | - | 41,000 | - |
2021.03 | 2021/05/12 | 実 | 515,952 | ↓ | 71,224 | ↑ | - | - | 56,219 | ↑ |
2021.03 | 2021/04/23 | 修正予 | 516,000 | ↑ | 71,200 | ↑ | - | - | 56,200 | ↑ |
2021.03 | 2021/02/12 | 修正予 | 515,000 | ↑ | 49,000 | ↓ | - | - | 27,000 | ↓ |
2021.03 | 2021/01/28 | Q3予 | 506,000 | → | 58,000 | → | - | - | 42,000 | → |
2021.03 | 2020/10/28 | 修正予 | 506,000 | ↑ | 58,000 | ↑ | - | - | 42,000 | ↑ |
2021.03 | 2020/07/30 | Q1予 | 495,000 | ↓ | 24,000 | → | - | - | 9,000 | ↑ |
2021.03 | 2020/05/13 | 当初予 | 510,000 | - | 24,000 | - | - | - | 7,000 | - |
2020.03 | 2020/05/13 | 実 | 482,732 | ↑ | 83,239 | ↑ | - | - | 40,753 | ↓ |
2020.03 | 2020/04/28 | 修正予 | 482,700 | ↑ | 83,200 | ↑ | - | - | 40,800 | ↑ |
2020.03 | 2020/01/30 | Q3予 | 475,000 | → | 75,000 | ↓ | - | - | 31,000 | ↓ |
2020.03 | 2019/10/28 | Q2予 | 475,000 | → | 88,000 | → | - | - | 36,000 | → |
2020.03 | 2019/07/29 | 修正予 | 475,000 | ↑ | 88,000 | ↑ | - | - | 36,000 | ↓ |
2020.03 | 2019/05/10 | 当初予 | 460,000 | - | 69,000 | - | - | - | 49,000 | - |
2019.03 | 2019/05/10 | 実 | 459,267 | ↓ | 57,884 | ↓ | - | - | 48,627 | ↑ |
2019.03 | 2019/04/19 | 修正予 | 459,300 | ↓ | 57,900 | ↑ | - | - | 48,600 | ↑ |
2019.03 | 2019/01/31 | Q3予 | 467,000 | → | 53,000 | → | 55,000 | → | 35,000 | → |
2019.03 | 2018/10/30 | Q2予 | 467,000 | → | 53,000 | → | 55,000 | → | 35,000 | → |
2019.03 | 2018/07/27 | Q1予 | 467,000 | → | 53,000 | → | 55,000 | → | 35,000 | → |
2019.03 | 2018/05/11 | 当初予 | 467,000 | - | 53,000 | - | 55,000 | - | 35,000 | - |
2018.03 | 2018/05/11 | 実 | 466,838 | ↓ | 88,173 | ↑ | 84,866 | ↑ | 53,448 | ↑ |
2018.03 | 2018/04/26 | 修正予 | 478,000 | ↑ | - | - | 60,900 | ↓ | 37,500 | ↓ |
2018.03 | 2018/01/30 | Q3予 | 474,000 | → | 72,000 | → | 72,000 | → | 55,000 | ↑ |
2018.03 | 2017/10/30 | Q2予 | 474,000 | ↑ | 72,000 | ↑ | 72,000 | ↑ | 47,000 | ↑ |
2018.03 | 2017/05/11 | 当初予 | 450,000 | - | 55,000 | - | 55,000 | - | 36,000 | - |
2017.03 | 2017/05/11 | 実 | 411,638 | ↑ | 52,759 | ↑ | 54,341 | ↑ | 28,991 | ↑ |
2017.03 | 2017/01/27 | Q3予 | 404,000 | ↑ | 46,000 | → | 46,000 | ↑ | 26,000 | ↑ |
2017.03 | 2016/10/27 | 当初予 | 398,000 | - | 46,000 | - | 44,000 | - | 25,000 | - |
2016.03 | 2016/05/11 | 実 | - | - | - | - | - | - | - | - |
2016.03 | 2016/01/27 | Q3予 | 403,000 | ↑ | 33,000 | ↑ | 32,500 | ↑ | 23,000 | ↑ |
2016.03 | 2015/10/28 | Q2予 | 401,000 | → | 29,000 | ↑ | 28,500 | ↑ | 20,000 | ↑ |
2016.03 | 2015/07/29 | Q1予 | 401,000 | ↑ | 27,000 | → | 26,500 | → | 18,000 | → |
2016.03 | 2015/05/11 | 当初予 | 392,000 | - | 27,000 | - | 26,500 | - | 18,000 | - |
2015.03 | 2015/05/11 | 実 | 371,370 | ↑ | 23,275 | ↑ | 23,331 | ↑ | 15,447 | ↑ |
2015.03 | 2015/01/29 | Q3予 | 371,000 | ↑ | 20,000 | → | 20,000 | ↑ | 12,500 | ↓ |
2015.03 | 2014/10/30 | Q2予 | 366,000 | ↑ | 20,000 | → | 19,500 | ↑ | 14,000 | ↑ |
2015.03 | 2014/07/30 | Q1予 | 352,000 | → | 20,000 | → | 19,000 | → | 12,000 | → |
2015.03 | 2014/05/08 | 当初予 | 352,000 | - | 20,000 | - | 19,000 | - | 12,000 | - |
2014.03 | 2014/05/08 | 実 | 387,693 | - | 42,142 | - | 40,631 | - | 20,060 | - |